Form 4: Neurocrine Legal Chief Exercises Stock Options
Insider Transaction Report
Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, exercised 3,349 stock options at $35.99 per share, increasing his direct common stock holdings to 46,754 shares.
Summary
- Darin Lippoldt, Chief Legal Officer of NEUROCRINE BIOSCIENCES INC (NBIX), reported a transaction on January 8, 2026.
- Lippoldt exercised 3,349 incentive stock options at a price of $35.99 per share.
- Following this transaction, Lippoldt's direct beneficial ownership of Common Stock increased to 46,754 shares.
- The exercised options were granted on February 5, 2016, vested monthly over four years, and were due to expire on February 5, 2026.
Sentiment
Score: 7
Explanation: The exercise of stock options by a key executive, increasing their direct ownership, is generally viewed as a positive signal of confidence in the company's future prospects, though it is a routine compensation event.
Positives
- The Chief Legal Officer, Darin Lippoldt, increased his direct beneficial ownership of company common stock by 3,349 shares, signaling continued confidence in the company's future.
- The exercise of options at $35.99 per share indicates a realized gain for the executive, reflecting past stock performance.
Future Outlook
This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.
Industry Context
This is a routine insider transaction filing for a publicly traded biotechnology company. Such filings are common and reflect executive compensation structures, where options are granted and exercised as part of long-term incentives.
Related Party Transactions
- Darin Lippoldt, Chief Legal Officer, exercised incentive stock options to acquire 3,349 shares of common stock from the issuer.
Stakeholder Impact
- Shareholders may view the increased direct ownership by a key executive as a positive indicator of management's alignment with shareholder interests and confidence in the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 02/05/2016 | Date incentive stock option was granted. |
| 01/08/2026 | Date of transaction: exercise of incentive stock options. |
| 01/12/2026 | Date the Form 4 was signed by the reporting person. |
| 02/05/2026 | Expiration date of the incentive stock options. |
Keywords
NBIX, Neurocrine Biosciences, Darin Lippoldt, Chief Legal Officer, Stock Options, Insider Transaction, Form 4, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.